Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous lidocaine effect on ED50 of remimazolam for laryngeal mask airway insertion in adults
ChiCTR2200063275Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam and lidocaine in None (2 arms), sponsored by The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University. Primary endpoint: Median effective bolus dose (ED50) of remimazolam for induction. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
remimazolamlidocaine
Beyond the preview
Go deeper on ChiCTR2200063275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063275.